Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma

References

• Anderson NS, Jensen MK, de Nully Brown P, et al. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognosis factors. Eur J Cancer 2002;38:401–408.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinic-pathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000;64:190–196.
   Google Scholar
• Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression free survival. J Clin Oncol 2002;20:1288–1294.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Piro L, Carrera C, Carson D, et al. Lasting remissions in hairy-cell leukemia induced by a single infusions of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117–1121.
   PubMed Web of Science ®Google Scholar
• Chadha P, Rademaker A, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241–246.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol J, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918–1926.
   PubMed Web of Science ®Google Scholar
• Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476–1481.
   PubMed Web of Science ®Google Scholar
• Liu E, Burian C, Miller W, et al. Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinemia. Br J Haematol 1998;103:690–695.
   PubMed Web of Science ®Google Scholar
• Blum K, Johnson J, Niedzwicki D, et al.; Cancer and Leukemia Group B Study 9153. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 1953. Cancer 2006;107:2817–2825.
   Web of Science ®Google Scholar
• Kay A, Saven A, Carrera C, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992;10:371–377.
   PubMed Web of Science ®Google Scholar
• Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001;40:551–564.
   PubMed Web of Science ®Google Scholar
• Byrd J, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludaribine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003;17:323–327.
   PubMed Web of Science ®Google Scholar
• Rummel M, Chow KU, Jager E, et al.Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol 1999;10:115–117.
   PubMed Web of Science ®Google Scholar
• Inwards D, Fishkin P, Hillman D, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Cenetral Cancer Treatment Group. Cancer 2008;113:108–116.
   PubMed Web of Science ®Google Scholar
• Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. Clin Oncol 2007;25:579–596.
   PubMed Web of Science ®Google Scholar
• Cheson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007:252:579–586.
   Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343–346.
   PubMedGoogle Scholar
• Kahl B, Longo W, Eickhoff J, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418–1423.
   PubMed Web of Science ®Google Scholar
• Wilson W, Gutierriz M, O’Connor P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 2002;29(Suppl. 2):41–47.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2059–2064.
   PubMed Web of Science ®Google Scholar
• Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab after cytotoxic chemotherapy leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003–4008.
   PubMed Web of Science ®Google Scholar
• Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883–893.
   PubMed Web of Science ®Google Scholar
• Eve HE, Linch D, Qian W, et al. Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomized phase II study. Leuk Lymphoma 2009;50:1709–1711.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius J, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–714.
   PubMed Web of Science ®Google Scholar
• Agatoff L, Connors J, Klasa R, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067–2078.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Bosq J, Munck J, et al. Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma 1997;26:567–575.
   Web of Science ®Google Scholar
• Temann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL); a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29–38.
   PubMed Web of Science ®Google Scholar
• Moller M, Pedersen N, Christensen B. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. Br J Haematol 2006;133:43–49.
   PubMed Web of Science ®Google Scholar
• Geisler C, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010;115:1530–1533.
   PubMed Web of Science ®Google Scholar
• Shah J, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008;112:2583.
   Web of Science ®Google Scholar
• Hoster E, Hasford J, Hermine O, et al. Confirmation of the mantle cell lymphoma international prognostic index in an independent prospective patient cohort. Blood 2009;114(Suppl. 1): Abstract 138.
   Google Scholar
• Smith S, His E, Bolwell B, et al. Validation of the mantle cell lymphoma international prognostic index: a single-center retrospective analysis. Am J Hematol 2010;85:454–456.
   PubMed Web of Science ®Google Scholar
• Gillis S, Amir G, Bennett M, et al. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxyadenosine therapy. Eur J Haematol 2001;66:7–10.
   PubMed Web of Science ®Google Scholar
• Kay AC, Saven A, Carrera CJ, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992;10:371–377.
   PubMed Web of Science ®Google Scholar
• Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 2010;116:2884–2896.
   PubMed Web of Science ®Google Scholar
• Wyczechowska D, Fabianowska-Majewska K. The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochem Pharmacol 2003;65:219–225.
   PubMed Web of Science ®Google Scholar
• Yu M, Epner E. The epigenetics of mantle cell lymphoma. Curr Treat Options Oncol 2007;8:375–381.
   PubMedGoogle Scholar